No Carolina / New York / Florida        Ph: 561.316.3330

Perspectum Partners with UT Southwestern Medical Center on Dallas Heart & Minds Study

What To Know

  • “As part of our efforts to improve the care of patients, we are using LiverMultiScan to assess the liver in this large DHMS cohort hoping to further our understanding of obesity phenotyping in the liver.
  • In the previous examinations, we extensively characterized obesity and cardiometabolic risk factors in our cohort – we are about to gain critical knowledge of how long-standing obesity and metabolic syndrome can affect liver health using LiverMultiScan by Perspectum.

Perspectum has announced a collaboration with UT Southwestern Medical Center, to include LiverMultiScan® technology in the Dallas Heart & Minds Study (DHMS).

Perspectum reports the DHMS initial aim was to improve the diagnosis, prevention and treatment of heart disease, over the years this has expanded to encompass metabolic diseases, such as fatty liver disease.

LiverMultiScan’s quantitative MRI technology will be used to measure chronic liver disease, enabling a deeper understanding of the interactions between genetics, environment and lifestyle on the health of the liver.

LiverMultiScan is currently being used across Dallas, and the US, to enable physicians to better diagnose and treat patients with disorders such as Fatty Liver Disease. Using a non-invasive MRI, the test gives metrics of liver tissue health that correlate with inflammation, fibrosis, fat, and iron.

“We are really excited to work with Perspectum on the Dallas Hearts and Minds Study, formerly known as Dallas Heart Study. In the previous examinations, we extensively characterized obesity and cardiometabolic risk factors in our cohort – we are about to gain critical knowledge of how long-standing obesity and metabolic syndrome can affect liver health using LiverMultiScan by Perspectum.” Dr. Jaret Berry, Principal Investigator, Dallas Heart and Minds Study

“As part of our efforts to improve the care of patients, we are using LiverMultiScan to assess the liver in this large DHMS cohort hoping to further our understanding of obesity phenotyping in the liver.” – Dr. Carlos Duncker, Medical Science Liaison, Perspectum.

Latest

CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Unlocking New Hope: Alzheimer’s Patients Join Amyloid-Targeting Therapy Study

0
The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting

0
Dr. Michael Newman, Indaptus’ Founder, Chief Scientific Officer, and lead author, commented, “The new data are consistent with our preclinical animal tumor model studies and provide evidence for our hypothesis that patented Decoy bacteria can activate a wide range of innate and adaptive human immune cells involved in fighting tumors.  This aligns with what we’ve observed in our ongoing Phase 1 clinical trial of Decoy20 – broad immune activation, as evidenced by transiently increased levels of many key cytokines and chemokines following single dose administration. These findings bolster our confidence in Decoy20's potential as a multifaceted immunotherapy.”
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia

0
“We are excited to present the first look at the safety and clinical activity of ELVN-001, which we believe supports the potential for ELVN-001 to address the limitations of the available active-site TKIs,” said Helen Collins, M.D., Chief Medical Officer of Enliven. “Across a wide dose range, ELVN-001 demonstrated activity in a heavily pre-treated patient population that includes post-asciminib patients, with a preliminary safety profile consistent with its highly selective design. Not only did all evaluable patients have improved or stable BCR::ABL1 transcript levels, but, importantly, 89% of all patients enrolled remain on study. We believe the initial data demonstrate the potential clinical utility of ELVN-001 for all types of patients, including those that are earlier in the treatment paradigm.”
CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

Ferring Presents Pivotal Phase 3 Efficacy and Safety Data for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASIPP 2024

0
The research, presented at the American Society of Interventional Pain Physicians (ASIPP) Annual Meeting, included a registrational Phase 3 trial and an integrated safety analysis of six clinical studies, as well as a real-world analysis of current treatment options and gaps in the clinical management of patients with newly-diagnosed LDH.

Reports breaking medical device and biotechnololgy news

About
Press Releases
Advertise
Privacy
Cookie Policy

Contact:  561.316.3330

Offices: No. Carolina / New York

© Medical Device News Magazine 2024

By using this website you agree to accept Medical Device News Magazine Privacy Policy